9.18% CAGR growth in Cancer Biologics Market by Product (Monoclonal antibodies, Cell and gene therapy, vaccines, and others), Route Of Administration, and Geography- Global forecast to 2028

NEW YORK, Feb. 19, 2024 /PRNewswire-PRWeb/ -- The cancer biologics market size is expected to grow by USD 51.08 billion from 2023 to 2028. In addition momentum of the market will be progressing at a CAGR of 9.18% during the forecast period, according to Technavio Research. The forecast period anticipates significant market share growth in the monoclonal antibodies segment, pivotal in targeted and immunotherapeutic treatments. These antibodies obstruct tumor progression by targeting specific proteins involved in angiogenesis, altering cancer cell behavior and interaction dynamics. Valued at USD 51.65 billion in 2018, this segment is witnessing accelerated expansion fueled by new drug approvals and a robust pipeline. Notable market offerings include Herceptin, Avastin, and KEYTRUDA. With monoclonal antibodies dominating the biologics pipeline, their presence is poised to drive segmental growth in the foreseeable future, making them indispensable assets in the fight against cancer.  This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read PDF Free Sample Report

North America is estimated to contribute 47% to the growth of the global market during the forecast period. 

Company Profile:

AstraZeneca Plc, Bayer AG, Biocon Ltd., Biogen Inc., Bristol Myers Squibb Co., Celltrion Co. Ltd, Cipla Ltd., Dr Reddys Laboratories Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Jazz Pharmaceuticals Plc., Johnson and Johnson, Lupin Ltd., Merck KGaA, Novartis AG, Ono Pharmaceutical Co. Ltd., Viatris Inc.

• Amgen Inc. - The company offers cancer biologics under the brand name Lumakras. This is offered for patients with KRAS G12C mutated advanced colorectal cancer CRC. To gain access to more vendor profiles available with Technavio, buy the report!

The escalating global prevalence of cancer is significantly propelling market expansion. Cancer, being a prevalent chronic ailment, is increasingly posing a substantial health challenge, correlating with heightened mortality rates worldwide. Primary factors contributing to cancer development include genetic mutations, environmental influences like tobacco usage and pollution, and evolving dietary habits. This surge in causative factors has notably fueled the uptick in global cancer cases, making it the second leading cause of death globally. In 2020 alone, there were 19.3 million new cancer diagnoses and 10 million cancer-related fatalities worldwide. Moreover, healthcare providers rely on cancer incidence data to guide procurement decisions for treatment equipment and medications, as well as to devise awareness and prevention initiatives. Consequently, the mounting incidence and prevalence of cancer among populations are anticipated to drive demand for cancer biologics, thereby shaping market growth trajectories.

• The untapped potential of cancer biologics in developing countries is an emerging trend shaping market growth.
• Patent expiry of major cancer biologics is a significant challenge hindering market growth. Strategic alliances among market vendors are a key trend in the cancer biologics market. Identify key trends, drivers, and challenges in the market. Download a sample to gain access to this information.

Related Reports:

The global pharmaceutical continuous manufacturing market size is estimated to grow by USD 548.94 million at a CAGR of 12.74% between 2023 and 2028.  

The global laryngeal cancer therapeutics market size is estimated to grow by USD 575.25 million at a CAGR of 5.43% between 2022 and 2027. 

ToC:

Executive Summary

Market Landscape

Market Sizing

Historic Market Sizes

Five Forces Analysis

Market Segmentation by Product 

Market Segmentation by Geography

Customer Landscape

Geographic Landscape

Drivers, Challenges, & Trends

Company Landscape

Company Analysis

Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com

SOURCE Technavio